This is a randomized, double-blind, placebo-controlled study, evaluating the effects of
BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety,
depression, global functioning and patient reported outcomes in patients with PTSD. Safety
and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of
blinded treatment followed by a 3 week follow-up period.